正大制藥集團

從二十世紀九十年代起，正大集團將自己多年積累的投資管理經(jīng)驗應(yīng)用于中國的制藥業(yè)，先后控股、參股了二十余家醫(yī)藥企業(yè)，順利完成了向蓬勃發(fā)展的健康產(chǎn)業(yè)的成功轉(zhuǎn)型，它的直接成果就是今天的正大制藥集團。如今，從秦巴山區(qū)到齊魯大地，從關(guān)中平原到黃海之濱，都分布著正大制藥集團控股參股的醫(yī)藥企業(yè)，這些企業(yè)在正大制藥集團參與投資后的數(shù)年間，都取得了迅猛的發(fā)展，成為中國制藥企業(yè)中的佼佼者；通過引進靈活的激勵機制，激活醫(yī)藥銷售網(wǎng)絡(luò)，正大制藥集團對中國國有醫(yī)藥企業(yè)進行了卓有成效的改造，培育起醫(yī)藥市場新的企業(yè)巨人，創(chuàng)造了諸多經(jīng)典范例。2005年江蘇正大天晴藥業(yè)股份有限公司和北京泰德制藥有限公司在中國醫(yī)藥工業(yè)企業(yè)年利潤總額排名中均榮列前50強。正大制藥集團在發(fā)展壯大的過程中，與中國的企業(yè)和員工共同分享醫(yī)藥工業(yè)發(fā)展的成果，有力地提升了中國大眾的健康水平。
2000年9月29日，正大制藥集團將在山東正大福瑞達制藥有限公司、江蘇正大天晴藥業(yè)股份有限公司和杭州正大青春寶藥業(yè)有限公司中的優(yōu)質(zhì)資產(chǎn)以中國生物制藥有限公司（股票代號：8027）的身份在香港聯(lián)合交易所創(chuàng)業(yè)板成功上市，正大制藥集團由此進入一個新的發(fā)展階段。中國生物制藥有限公司于二零零三年十二月八日成功轉(zhuǎn)至香港聯(lián)合交易所主板上市，股份代號為1177。作為卜蜂—正大集團的二級集團，正大制藥集團得到這一在東南亞地區(qū)最具規(guī)模企業(yè)集團的全力支持，并得以充分利用正大集團在中國多年的投資實踐所積累的豐富經(jīng)驗，竭誠為繁榮中國的醫(yī)藥衛(wèi)生事業(yè)而努力工作。
中國經(jīng)濟的飛速發(fā)展，使海外華人倍受鼓舞，正大制藥集團對中國的發(fā)展前景充滿信心，并將繼續(xù)堅定不移地推進在中國的投資戰(zhàn)略，集團堅信，只要竭力發(fā)揮中外雙方各自的優(yōu)勢，就能夠以一流的人才、一流的設(shè)備、一流的管理，為顧客生產(chǎn)出一流的產(chǎn)品，為人類的健康作出卓越的貢獻，同時也為合營雙方創(chuàng)造令人滿意的經(jīng)濟效益。
“愛會帶給你無限溫暖，也會帶給你快樂和健康”，秉承正大集團的價值觀念和企業(yè)文化，我們相信，擁有健康，才能享受快樂，通過積極投身參與中國的醫(yī)藥產(chǎn)業(yè)，正大制藥集團愿與更多的伙伴和顧客分享快樂。



CHIA TAI PHARMACEUTICAL GROUP
Since the 1990s, Chia Tai Group has adopted the many-year-accumulated investing and managing experience into the pharmacy in China. It has charged or shared ten medical enterprises successively, and has successfully finished the conversion to the flourishing exuberant industry. The direct harvest is Chia Tai Pharmaceutical Group today. Nowadays, the medical enterprises held or shared by Chia Tai Pharmaceutical Group widely situate at many cities of China, from the mountainous area of Qinba to the area of Qilu, from the plain of Guanzhong to the shore of Yellow Sea. These enterprises have developed rapidly during the period of investment of Chia Tai Pharmaceutical Group, and have become the outstanding ones among pharmacy enterprises in China. By introducing flexible inspiring mechanism for people and activating the sale network, Chia Tai Pharmaceutical Group has fruitfully reformed nation-owned medical enterprises of China, and also has cultivated a new giant in the medical market. It has created a good many classical paradigms, for example each of the after-tax profits for both Jiang Su Chia Tai-TianQing Pharmaceutical Co. Ltd and Beijing Tide Pharmaceutical Co., Ltd. has ranked among the first-one-hundred place in all the pharmaceutical enterprises in China. During the booming of Chia Tai Pharmaceutical Group, it shares the developmental fruits of medical industry with Chinese enterprises and employees and has greatly increased the healthy level of ordinary Chinese population.
In September 29th, 2000, Chia Tai Pharmaceutical Group successfully listed in the stock market---the Growth Enterprise Market of the Stock Exchange of HONG KONG Limited by the name of Sino Biopharmaceutical Ltd (stock No. 8027),.This listed company was consisted of the high quality assets of the Group. They included Shan Dong Chia Tai Freda Pharmaceutical Co. Ltd, Jiang Su Chia Tai-TianQing Pharmaceutical Co. Ltd and Hang Zhou Chia Tai Qing Chun Bao Pharmaceutical Co. Ltd. Since then, Chia Tai Pharmaceutical Group has entered a new developing period. In March 12, 2002, Sino Biopharmaceutical Limited listed on the Main Board of the Hong Kong Stock Exchange (Stock Code number 1177). As a second level group of Choroen Pokphand – Chia Tai Group, Chia Tai Pharmaceutical Group has received the all-out support from this largest scale enterprise group in Southeast Asia, and has gained the opportunity to make full use of the rich experience of Chia Tai Group during the many-year investment practice in China in order to wholeheartedly make efforts for the flourish of the medical health service in China.
The fast development of Chinese economy makes Chinese living abroad greatly inspirited, and Chia Tai Pharmaceutical Group is fully confident of the prospect of the development of China. It will unswervingly continue its investment stratagem in China. The Group believes that as long as it brings into full play of the advantages of both China and foreign countries, it will be able to manufacture the top-ranking products for customers by the high-class talented people, equipment and management, and be able to make distinguishing contributions to the health of human beings and at the same time to create satisfying economical interests for both sides of the copartner.
“ Love will bring you infinite warmth as well as happiness and health.” Taking the Chia Tai Group’s view of value and enterprise culture, we believe that only possessing health one can enjoys happiness. By energetically taking part in Chinese medical industry, Chia Tai Pharmaceutical Group is ready to share happiness with more partners and customers.